APTX

NYX-783

Post-traumatic stress disorder (PTSD)

Stage (next event)

Expected Date

Phase 2 To be initiated

H2 2020

Catalyst Info & Data Links

TITLE: NYX-783 for Post-traumatic stress disorder (PTSD) Phase 2 to be initiated 

  • Clinical Trial (NCT04044664) Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder


WHAT IS THE NEXT CATALYST EVENT?

  • Phase 2 To be initiated


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2021


PRIOR DATA/EVENTS

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • NMDA receptors are critically important in normal brain and nervous system function and play a key role in regulating how neurons connect to each other. The activation and opening of NMDA receptors, in response to the binding of specific neurotransmitters including glutamate, triggers a cascade of events that results in synaptic plasticity. This activation may be a beneficial therapeutic approach to treating disorders of the brain and nervous system.

Updated by MV

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon